ERYTHROPOIETIN PHYSIOLOGY & PHARMACOLOGY IN INFANTS

促红细胞生成素生理学

• 批准号: 6566521
• 负责人: JOHN Andrew WIDNESS
• 金额: $ 17.79万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6566521
• 关键词: anemia; blood disorder chemotherapy; clinical research; drug administration rate /duration; drug administration routes; drug screening /evaluation; erythropoietin; human subject; human therapy evaluation; newborn human (0-6 weeks); recombinant proteins

The long-term objective of this study is to develop mechanistically based strategies for the optimal administration of recombinant human erythropoietin (r-HuEPO) to treat anemia in preterm neonates.

这项研究的长期目标是制定基于机械的策略，以最佳地施用重组人红细胞生成素（R-Huepo）来治疗早产新生儿中的贫血。